Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2017

View Archived Issues

Florida Department of Health awards grant for gp96-based Zika vaccine development

DSMB recommends continuation of phase III trial of apabetalone

New phase III outcomes program for empagliflozin in chronic heart failure

Kisqali available for U.S. order through Biologics

Efficacy seen with CLS-003 digoxin/furosemide patch in treating cutaneous warts

Biosceptre obtains conditional ethics committee approval for phase I trial of BIL-03s

Phase II results for macitentan presented for pulmonary hypertension

Ergomed initiates European phase IIb study of PeproStat

Achillion Pharmaceuticals describes novel complement factor D inhibitors

Gachon University, Bio-Medical Science and Yoo Young Pharm patent mTOR inhibitors

Umecrine Cognition initiates phase Ib/IIa study of GR-3027 for hepatic encephalopathy

Yang Ji Chemical Co. and Han Wha Pharma Co. describe new JAK inhibitors

Sunshine Lake Pharma patents cathepsin K inhibitors

Abbvie discloses new sphingosine 1-phosphate receptor 5 modulators

Janssen-Cilag conducts oral bioavailability trial of JNJ-63623872/oseltamivir phosphate

Saniona updates plans for phase IIa study of Tesomet in Prader-Willi syndrome

AB Science's phase II/III trial of masitinib in ALS meets primary endpoint

Ipsen returns LRRK2-based research program in Parkinson's to Oncodesign

Japanese collaborators announce open innovation research on new cancer immunotherapy

Study suggests PARP-1 is a therapeutic target for treating Merkel cell carcinoma

CBT Pharmaceuticals begins phase I study of CBT-501 in advanced, relapsed or recurrent solid tumors

MDR3 and MRP1 found as poor prognostic markers in Wilm's tumor after SIOP-93-01 treatment protocol

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...